GO
Loading...

United Therapeutics Corp

More

  • March 10- The U.S. Food and Drug Administration said it approved United Therapeutics Corp's drug to treat an aggressive form of neuroblastoma, a rare cancer that typically occurs in children below 5 years. Wedbush Securities analyst Liana Moussatos estimated there are about 425 high-risk patients in the United States and 1,275 worldwide.

  • March 10- The U.S. Food and Drug Administration said it approved United Therapeutics Corp's drug to treat neuroblastoma, a rare cancer that typically occurs in children below 5 years. Unituxin is the first drug approved to treat high-risk neuroblastoma patients who have a greater chance of tumors recurring or progressing after chemotherapy.

  • March 10- The U.S. Food and Drug Administration said it had approved United Therapeutics Corp's drug to treat neuroblastoma, a rare form of cancer that most often occurs in young children. United Therapeutics' drug, Unituxin, marks the first approval for a therapy aimed at high-risk patients affected by the cancer that forms from immature nerve cells.

  • Hedge funder offers $1 million to cure...aging? Monday, 15 Sep 2014 | 11:19 AM ET
    Doctor holding elderly hand

    A hedge fund manager is the latest to embark on one of the most ancient of human quests: immortality.

  • Two momentum names that investors should buy now Wednesday, 21 May 2014 | 6:43 PM ET
    Momentum trades alive: ARCB, UTHR

    Nili Gilbert of Matarin Capital says there are still some momentum names that will continue to outperform.

  • Cramer’s homework uncovers intriguing stock Friday, 10 Jan 2014 | 6:52 PM ET
    Cramer’s Homework: Less Familiar Stocks, but Less Attractive?

    Sometimes Cramer tells a caller that he needs to do homework before he can make a decision on a stock. He's not kidding.

  • Midday Movers: Apple, Target, Micron & More Monday, 23 Dec 2013 | 12:35 PM ET

    Some of Monday's midday movers:

  • Lightning Round: Pier 1, Green Mountain & More Monday, 2 Dec 2013 | 6:48 PM ET

    It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Lightning Round: Facebook, Deere & More Wednesday, 9 Oct 2013 | 6:40 PM ET

    It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Lightning Round: Yahoo!, AMD & More Wednesday, 2 Oct 2013 | 6:41 PM ET

    It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Predictions for FDA Drug Approvals Tuesday, 12 Mar 2013 | 12:13 PM ET

    TheStreet.com reports its investor predictions for FDA drug approvals in 2013: Bad news for Arena Pharmaceuticals, Delcath Systems and Aveo Pharmaceuticals, but Sarepta Therapeutics and Ziopharm are among the winners.

  • FDA declines United's drug application Tuesday, 23 Oct 2012 | 6:16 PM ET

    SILVER SPRING, Md.-- United Therapeutics Corp. said Tuesday that the U.S. Food and Drug Administration declined its application for an extended-release tablet version of its pulmonary arterial hypertension drug treprostinil.

  • How 3D Printers Are Reshaping Medicine Wednesday, 10 Oct 2012 | 12:25 PM ET
    Bioprinting

    Printing off a kidney or another human organ may sound like something out of science fiction, but with advancements in 3D printing technology, the idea may not be so far-fetched.

  • Cramer makes the call on viewers' favorite stocks.

  • Stocks on the Move Now: Michael Kors Skyrockets Tuesday, 14 Feb 2012 | 12:53 PM ET
    By The Numbers | Stocks on the Move Now

    Shares of Michael Kors spiked Tuesday, as the luxury retailer reported a 47 percent increase in fiscal third-quarter earnings. 

  • In breaking news CNBC's Scott Cohn says a former Nasdaq employee has pled guilty to securities fraud for insider trading.

  • S&P May Reach 1400-1430 by End of May: Strategist Tuesday, 10 May 2011 | 11:09 AM ET

    The S&P may reach the 1,400 to 1,430 level between now and the end of May, said Michael McGervey, president of McGervey Wealth Management. He explained his thinking to CNBC.

  • Exclusive Picks From Street’s Top Biotech Analyst Friday, 19 Nov 2010 | 5:24 PM ET

    It appears the biotech news flow is heating up.  But should you get in before year's end? 

  • Sector Trade: Biotech Monday, 28 Sep 2009 | 5:32 PM ET

    Investors are placing their bets on the next M&A deal in biotech. Where should you be looking?

  • Dendreon Makes The List...Again Friday, 25 Sep 2009 | 12:44 PM ET

    2,226 percent. That is the astronomical increase in shares of baby biopharma Vanda so far this year. And it's the prime historical example of "Biotech Takeouts and Breakouts" Bernstein's Geoffrey Porges uses in a sequel research note to clients he put out today.